Could a pill replace chemo for some breast cancers?
NCT ID NCT06107673
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial compares a daily pill (dalpiciclib) plus hormone therapy against standard chemotherapy for postmenopausal women with a specific type of breast cancer (ER+ HER2-). The goal is to see if the pill combination works as well as chemo but with fewer side effects. About 144 participants will be enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dalpiciclib (a targeted cancer pill) plus an aromatase inhibitor (hormone therapy)
What this could lead to
If successful, this could offer a less toxic, pill-based alternative to chemotherapy for certain postmenopausal breast cancer patients.
What could go wrong
This is a small, early phase II trial, so results may not confirm non-inferiority or translate to broader populations. Side effects from the drug combination are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••